Search Results - "Till, Cathee"

“When Offered to Participate”: A Systematic Review and Meta-Analysis of Patient Agreement to Participate in Cancer Clinical Trials by Unger, Joseph M, Hershman, Dawn L, Till, Cathee, Minasian, Lori M, Osarogiagbon, Raymond U, Fleury, Mark E, Vaidya, Riha

“…Abstract Background Patient participation in clinical trials is vital for knowledge advancement and outcomes improvement. Few adult cancer patients participate…”
Get full text

Comorbidities and Risk of Chemotherapy-Induced Peripheral Neuropathy Among Participants 65 Years or Older in Southwest Oncology Group Clinical Trials by Hershman, Dawn L, Till, Cathee, Wright, Jason D, Awad, Danielle, Ramsey, Scott D, Barlow, William E, Minasian, Lori M, Unger, Joseph

“…Neuropathy is a debilitating toxicity associated with various chemotherapy agents. We evaluated the association between common comorbid conditions and the…”
Get full text

Risk prediction of hepatitis B or C or HIV among newly diagnosed cancer patients by Unger, Joseph M, Till, Cathee, Hwang, Jessica P, Arnold, Kathryn B, Leblanc, Michael, Hershman, Dawn L, Ramsey, Scott D

“…Abstract Background Screening for viral infection in cancer patients is inconsistent. A mechanism to readily identify cancer patients at increased risk of…”
Get full text

Omega-3 fatty acid use for obese breast cancer patients with aromatase inhibitor-related arthralgia (SWOG S0927) by Shen, Sherry, Unger, Joseph M., Crew, Katherine D., Till, Cathee, Greenlee, Heather, Gralow, Julie, Dakhil, Shaker R., Minasian, Lori M., Wade, James L., Fisch, Michael J., Henry, N. Lynn, Hershman, Dawn L.

“…Purpose Although aromatase inhibitors (AIs) prolong survival in post-menopausal breast cancer (BC) patients, AI-associated arthralgia can lead to…”
Get full text

Two-Year Trends of Taxane-Induced Neuropathy in Women Enrolled in a Randomized Trial of Acetyl-L-Carnitine (SWOG S0715) by Hershman, Dawn L, Unger, Joseph M, Crew, Katherine D, Till, Cathee, Greenlee, Heather, Minasian, Lori M, Moinpour, Carol M, Lew, Danika L, Fehrenbacher, Louis, Wade, James L, Wong, Siu-Fun, Fisch, Michael J, Lynn Henry, N, Albain, Kathy S

“…Abstract Background Chemotherapy-induced peripheral neuropathy (CIPN) is a common and disabling side effect of taxanes. Acetyl-L-carnitine (ALC) was…”
Get full text

Association between body mass index and response to duloxetine for aromatase inhibitor‐associated musculoskeletal symptoms in SWOG S1202 by Henry, N. Lynn, Unger, Joseph M., Till, Cathee, Schott, Anne F., Crew, Katherine D., Lew, Danika L., Fisch, Michael J., Moinpour, Carol M., Wade, James L., Hershman, Dawn L.

“…Background Aromatase inhibitor (AI)‐associated musculoskeletal symptoms (AIMSS) negatively impact adherence to and persistence with therapy. In SWOG S1202,…”
Get full text

Healthcare utilization and cost of care in elderly breast cancer patients enrolled in SWOG clinical trials by Hershman, Dawn L., Till, Cathee, Wright, Jason D., Accordino, Melissa, Vaidya, Riha, Barlow, William E., Ramsey, Scott, Unger, Joseph M.

“…Importance Patients with cancer are at risk for unplanned hospitalizations during treatment which can increase the cost of care. Objectives To determine…”
Get full text

Serum 25-Hydroxyvitamin D Concentrations and Risk of Prostate Cancer: Results from the Prostate Cancer Prevention Trial by SCHENK, Jeannette M, TILL, Cathee A, TANGEN, Catherine M, GOODMAN, Phyllis J, XIAOLING SONG, TORKKO, Kathleen C, KRISTAL, Alan R, PETERS, Ulrike, NEUHOUSER, Marian L

“…Epidemiologic studies have reported inconsistent associations of vitamin D and prostate cancer risk; however, few have adequately controlled for detection bias…”
Get full text

Trends in Obesity Prevalence Among Patients Enrolled in Clinical Trials for Obesity-Related Cancers, 1986 to 2016 by Vaidya, Riha, Till, Cathee, Greenlee, Heather, Hershman, Dawn L, Unger, Joseph M

“…Obesity rates have risen in the United States since the 1980s. Several studies have shown links between obesity and the incidence of specific cancer types, but…”
Get full text

Men with Low Serum Cholesterol Have a Lower Risk of High-Grade Prostate Cancer in the Placebo Arm of the Prostate Cancer Prevention Trial by PLATZ, Elizabeth A, TILL, Cathee, GOODMAN, Phyllis J, PARNES, Howard L, FIGG, William D, ALBANES, Demetrius, NEUHOUSER, Marian L, KLEIN, Eric A, THOMPSON, Ian M, KRISTAL, Alan R

“…Background: Several prospective studies suggest that use of cholesterol-lowering statin drugs is inversely associated with advanced stage and possibly…”
Get full text

Variations in prostate biopsy recommendation and acceptance confound evaluation of risk factors for prostate cancer: Examining race and BMI by Tangen, Catherine M., Schenk, Jeannette, Till, Cathee, Goodman, Phyllis J., Barrington, Wendy, Lucia, M. Scott, Thompson, Ian M.

“…•Factors unrelated to cancer risk can impact which men receive a prostate biopsy.•Prostate cancer is prevalent so factors that increase the likelihood of a…”
Get full text

Serum Lycopene Concentration and Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial by KRISTAL, Alan R, TILL, Cathee, PLATZ, Elizabeth A, XIAOLING SONG, KING, Irena B, NEUHOUSER, Marian L, AMBROSONE, Christine B, THOMPSON, Ian M

“…Lycopene has been promoted for prostate cancer prevention, despite the inconsistency of scientific evidence. This nested case-control study examined whether…”
Get full text

Circadian genes and risk of prostate cancer in the prostate cancer prevention trial by Chu, Lisa W., Till, Cathee, Yang, Baiyu, Tangen, Catherine M., Goodman, Phyllis J., Yu, Kai, Zhu, Yong, Han, Summer, Hoque, Ashraful M., Ambrosone, Christine, Thompson, Ian, Leach, Robin, Hsing, Ann W.

“…Circadian genes have been considered as a possible biological mechanism for the observed relationship between circadian rhythm disruptions and increased risk…”
Get full text

Associations Between Polymorphisms in Genes Related to Oxidative Stress and DNA Repair, Interactions With Serum Antioxidants, and Prostate Cancer Risk: Results From the Prostate Cancer Prevention Trial by Gong, Zhihong, Platek, Mary E, Till, Cathee, Goodman, Phyllis J, Tangen, Catherine M, Platz, Elizabeth A, Neuhouser, Marian L, Thompson, Ian M, Santella, Regina M, Ambrosone, Christine B

“…Study of polymorphisms in genes related to the generation and removal of oxidative stress and repair of oxidative DNA damage will lead to new insights into the…”
Get full text

Serum Retinol and Carotenoid Concentrations and Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial by Nash, Sarah H, Till, Cathee, Song, Xiaoling, Lucia, M Scott, Parnes, Howard L, Thompson, Jr, Ian M, Lippman, Scott M, Platz, Elizabeth A, Schenk, Jeannette

“…Findings from epidemiologic studies examining associations of serum retinol and carotenoids with prostate cancer risk have been inconsistent. This case-control…”
Get full text

Trichomonosis and subsequent risk of prostate cancer in the Prostate Cancer Prevention Trial by Sutcliffe, Siobhan, Alderete, John F., Till, Cathee, Goodman, Phyllis J., Hsing, Ann W., Zenilman, Jonathan M., De Marzo, Angelo M., Platz, Elizabeth A.

“…We previously observed a positive association between a history of trichomonosis, a sexually transmitted infection caused by the protozoan, Trichomonas…”
Get full text

Finasteride concentrations and prostate cancer risk: results from the Prostate Cancer Prevention Trial by Chau, Cindy H, Price, Douglas K, Till, Cathee, Goodman, Phyllis J, Chen, Xiaohong, Leach, Robin J, Johnson-Pais, Teresa L, Hsing, Ann W, Hoque, Ashraful, Tangen, Catherine M, Chu, Lisa, Parnes, Howard L, Schenk, Jeannette M, Reichardt, Juergen K V, Thompson, Ian M, Figg, William D

“…In the Prostate Cancer Prevention Trial (PCPT), finasteride reduced the risk of prostate cancer by 25%, even though high-grade prostate cancer was more common…”
Get full text

Variation in genes involved in the immune response and prostate cancer risk in the placebo arm of the Prostate Cancer Prevention Trial by Winchester, Danyelle A., Till, Cathee, Goodman, Phyllis J., Tangen, Catherine M., Santella, Regina M., Johnson-Pais, Teresa L., Leach, Robin J., Xu, Jianfeng, Zheng, S. Lilly, Thompson, Ian M., Lucia, M. Scott, Lippmann, Scott M., Parnes, Howard L., Dluzniewski, Paul J., Isaacs, William B., De Marzo, Angelo M., Drake, Charles G., Platz, Elizabeth A.

“…BACKGROUND We previously found that inflammation in benign prostate tissue is associated with an increased odds of prostate cancer, especially higher‐grade…”
Get full text

Finasteride modifies the relation between serum C-peptide and prostate cancer risk: results from the Prostate Cancer Prevention Trial by Neuhouser, Marian L, Till, Cathee, Kristal, Alan, Goodman, Phyllis, Hoque, Ashraful, Platz, Elizabeth A, Hsing, Ann W, Albanes, Demetrius, Parnes, Howard L, Pollak, Michael

“…Hyperinsulinemia and obesity-related metabolic disturbances are common and have been associated with increased cancer risk and poor prognosis. To investigate…”
Get full text

History of Diabetes and Survival Outcome Among Participants 65 Years or Older in SWOG Clinical Trials by Hershman, Dawn L, Till, Cathee, Wright, Jason D, Ramsey, Scott, Barlow, William E, Unger, Joseph M

“…Diabetes is common, increases with age, and may affect outcomes among people with cancer. Understanding the association between diabetes and cancer outcome is…”
Get more information